PROTEIN POLYMER TECHNOLOGIES SIGNS AGREEMENT TO PROVIDE
BIOMATERIALS FOR USE IN PREVENTION OF POST-SURGICAL ADHESIONS
SAN DIEGO, (CA) --July
16, 2007 -- Protein Polymer Technologies, Inc. (OTC BB:PPTI.OB
- News), a biotechnology device company that is a pioneer
in protein design and synthesis, announced today that
they have entered into an agreement with a multinational
biotechnology device company. According to the agreement,
PPTI will provide genetically engineered protein polymer
biomaterials for use in the prevention of post-surgical
adhesions. "This agreement further demonstrates
our core competency; developing novel protein polymer
biomaterials for challenging medical applications such
as the prevention of surgical adhesions," said William
N. Plamondon, Chief Executive Officer of PPTI. "Additionally,
it furthers the progression of our plan to establish
relationships with partners that will ultimately market
the products. This relationship adds to the six others
we have in product development which includes our license
agreements with Spine Wave, Inc. and Genencor International,
Inc."
Post-operative adhesions, unintended
attachments between distinct tissues and organs in the
body, occur after most surgical procedures. Most notable
are the complications that arise from adhesions after
abdominal and gynecological surgery. Studies have shown
that between 55% and 100% of patients developed adhesions
within six months of surgery. In severe cases, adhesions
can cause pain, obstructions and infertility. More than
300,000 Americans are hospitalized each year at a cost
of $1.3 billion to undergo surgery to remove adhesions.
PPTI believes its protein polymer materials can improve
the outcome of abdominal and gynecological surgery by
substantially reducing adhesions.
PPTI is also in discussions with several U.S. and international
biotechnology and medical device companies, which are
evaluating PPTI's surgical sealant and drug delivery
product applications. These products are intended to
aid in the closure of surgical incisions and tissue trauma
reducing, for example, the incidence of post-operative
bleeding and the delivery locally of therapeutic agents. "We
have been successful here because of the competencies
we've developed in manufacturing products, supporting
clinical trials, and engineering application and delivery
systems that support the biomaterials platform that we
own," said Joe Cappello, Chief Technology Officer
of PPTI.
Investor/Media Contact:
Erin Davis
Director of Communications and Investor Relations
Protein Polymer Technologies, Inc.
(858) 558-6064 x 120
Email Contact |
|
About
Protein Polmer Technologies
Protein Polymer Technologies, Inc. is a biotechnology company that discovers
and develops innovative therapeutic devices to improve medical and surgical
outcomes. The Company focuses on developing technology and products to be used
for soft tissue augmentation, tissue adhesives and sealants, wound healing
support and drug delivery devices. Protein Polymer Technologies' proprietary
protein-based biomaterials are uniquely tailored to optimize clinical performance
and contain no human or animal components that could potentially transmit or
cause disease. The company is headquartered in San Diego, California. For additional
information about the company, please visit http://www.ppti.com.
To date, PPTI has been issued twenty-six U.S. Patents on its core technology
with corresponding issued and pending patents in key international markets.
Safe Harbor
This press release contains forward-looking statements
that are based on management's views and expectations.
Actual results could differ materially from those expressed
here; further, the Company is not obligated to comment
specifically on those differences. Risks associated with
the Company's activities include raising adequate capital
to continue operations, scientific and product development
uncertainties, competitive products and approaches, continuing
collaborative partnership interest and funding, regulatory
testing and approvals, and manufacturing scale up. The
reader is encouraged to refer to the Company's 2006 Annual
Report Form 10-KSB, and recent
filings with the Securities and Exchange Commission,
copies of which are available from the Company, to further
ascertain the risks associated with the above statements.
